Skip to content
  • Home
  • IOncology
  • Infectious Desease Frontier
  • IHepatology
  • Hematology Frontier
  • Conference topics
  • Experts Interviews
  • Informations
  • Live Broadcasting
  • Logout
MediaMedic

Connecting Medical Expertise through Media

  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations

# Interview

Home » # Interview » Page 2
Current treatment status and challenges for intermediate and advanced stage HCC

Current treatment status and challenges for intermediate and advanced stage HCC

Posted by By Xiaorong JI 2024.02.18
<Hepatology Digest>: What is the efficacy of current treatment strategies for intermediate and advanced stage HCC, and what are the challenges and limitations associated with them?
Read More
The mechanism of tumor microenvironment affecting the occurrence and development of HCC

The mechanism of tumor microenvironment affecting the occurrence and development of HCC

Posted by By Xiaorong JI 2024.02.18
<Hepatology Digest>: How does the tumor immune microenvironment affect the efficacy of precision HCC therapy?
Read More
The worldwide prevalence trend of MASLD

The worldwide prevalence trend of MASLD

Posted by By Xiaorong JI 2024.02.18
<Hepatology Digest>: What is the prevalence trend of MASLD globally? Are there specific regions or populations that are more affected and why?
Read More
What is the association between the microbiome and autoimmune liver diseases?

What is the association between the microbiome and autoimmune liver diseases?

Posted by By Xiaorong JI 2024.02.18
<Hepatology Digest>: What role does microbiomics play in the pathogenesis of autoimmune liver diseases? What current research findings have revealed the association between the microbiome and autoimmune liver diseases?
Read More
The U.S. Experience in HCV Screening, Linkage, and Treatment

The U.S. Experience in HCV Screening, Linkage, and Treatment

Posted by By Xiaorong JI 2024.01.31
Read More
Pinnacle Conversation | Advancements in the Diagnosis and Treatment of Metabolism-Related Fatty Liver Disease: Discussing New Developments, Sharing Experiences from Singapore and the United States, and Addressing Global Progress

Pinnacle Conversation | Advancements in the Diagnosis and Treatment of Metabolism-Related Fatty Liver Disease: Discussing New Developments, Sharing Experiences from Singapore and the United States, and Addressing Global Progress

Posted by By Xiaorong JI 2024.01.31
Read More
Interview with AASLD President: A Resurgence of Vitality in the Field of Liver Disease, Highlights Galore at 2023 Annual Meeting

Interview with AASLD President: A Resurgence of Vitality in the Field of Liver Disease, Highlights Galore at 2023 Annual Meeting

Posted by By Xiaorong JI 2024.01.31
Read More
Four New Insights into the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Four New Insights into the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Posted by By Xiaorong JI 2024.01.31
Read More
Progress in the Treatment of Intermediate and Advanced HCC, Highlighting the Value of Systemic Therapy

Progress in the Treatment of Intermediate and Advanced HCC, Highlighting the Value of Systemic Therapy

Posted by By Xiaorong JI 2024.01.31
Read More
The main mechanisms and development prospects of HCC combination therapy

The main mechanisms and development prospects of HCC combination therapy

Posted by By Xiaorong JI 2024.01.31
Read More

Posts pagination

Previous page 1 2 3 Next page
Recent Posts
  • ESMO China Voice | Professor Jiesong Wang: The iPET-NCCN-IPI Model May Optimize Risk Stratification in Diffuse Large B-Cell Lymphoma
  • ESMO China Voice | Dr. Sicong Zhang: Refractory DLBCL Patients Share Similar Immune Signatures
  • ESMO China Voice | Dr. Cong Sun: Grade 3B Follicular Lymphoma Is an Independent Risk Factor Affecting Both PFS and OS
  • ESMO China Voice | Prof. Liang Wang: CD19/CD22 Bispecific CAR-T Therapy Demonstrates Remarkable Efficacy and Safety in R/R LBCL
  • 13th FACO Annual Academic Conference Grandly Held in Shanghai! Leading Experts from China, Japan, and South Korea Gather to Foster Clinical Oncology
Recent Comments
    Archives
    • October 2025
    • September 2025
    • August 2025
    • July 2025
    • June 2025
    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • January 2024
    • December 2023
    • November 2023
    • October 2023
    • August 2023
    Categories
    • Artificial intelligence
    • Hematology Frontier
    • Infectious Disease Frontier
    • International Hepatology
    • IOncology
    • Live broadcasting
    • Uncategorized
    • UroStream
    • LinkedIn
    • Twitter
    • Mail
    Related Media:
    Copyright 2025 — MediaMedic. All rights reserved. Blogun WordPress Theme
    Media Medic Publishing Company Limited(HK)
    赛美出版有限公司（香港）
    Scroll to Top